[
  {
    "ts": "2025-09-26T11:00:00+00:00",
    "headline": "Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol",
    "summary": "FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH) HoFH is an inherited condition characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) Initial Evkeeza approval based on placebo-controlled trial showing Evkeeza, when added to standard lipid-lowering therapies, could lower LDL-C by about 50% compared to placebo in this high unmet need population TARRYTOWN, N.Y., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Reg",
    "url": "https://finance.yahoo.com/news/evkeeza-evinacumab-dgnb-angptl3-antibody-110000540.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "028b77db-9d55-334b-a8fc-b5b839178cb8",
      "content": {
        "id": "028b77db-9d55-334b-a8fc-b5b839178cb8",
        "contentType": "STORY",
        "title": "Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol",
        "description": "",
        "summary": "FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH) HoFH is an inherited condition characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) Initial Evkeeza approval based on placebo-controlled trial showing Evkeeza, when added to standard lipid-lowering therapies, could lower LDL-C by about 50% compared to placebo in this high unmet need population TARRYTOWN, N.Y., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Reg",
        "pubDate": "2025-09-26T11:00:00Z",
        "displayTime": "2025-09-26T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
          "originalWidth": 800,
          "originalHeight": 126,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ohIVokMiKClSVTQVwyB2lw--~B/aD0xMjY7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142.cf.webp",
              "width": 800,
              "height": 126,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YuYzNeQcIK6rRYN1HdT6UA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/evkeeza-evinacumab-dgnb-angptl3-antibody-110000540.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/evkeeza-evinacumab-dgnb-angptl3-antibody-110000540.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]